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1 Introduction
Intrauterine growth retardation (IGR), is a major
cause of perinatal morbidity-mortality. Its diag-
nosis and treatment constitutes one of the most
important challenges of present day obstetrics [2].
Many factors are related to fetal development and
growth; therefore, there are many reasons which
may lead to low birth infants [4, 8]. A small
percentage of IGR may have a maternal origin
including diabetes, pregnancy-related hypertensive
states and cardiopathies. In most instances the
etiology of IGR is unknown.
The absence of a uniform etiology may help one
understand the existence of the large number of
treatments suggested for correcting the problem.
This includes the lack of positive results, since
IGR fetuses do not respond to solid etiopatho-
genic bases, but rather up on symptomatic aspects
or very specific etiological factors of the disease
[4,8].
This report is a prospective study of the treatment
of IGR of unknown etiology which is based on a
long hospital stay and betamimetic drug admin-
istration.
2 Material and methods
A group of 98 women in the course of their third
trimester of pregnancy was studied. The ultrason-
ographic studies performed had raised the possi-
bility of IGR. We understand IGR to be a differ-
ence greater than two weeks between menstrual
dating and ultrasonographic dating based upon
biparietal diameter, cephalic area and perimeter,
abdominal area and perimeter which were studied
with 2 measurements performed 15 days apart. All
the patients were included in a IGR screening
protocol from the beginning of their pregnancy.
The screening included both serial ultrasono-
graphic studies and menstrual establishment of
gestational age.
The patients were randomly assigned to the two
groups. Both groups were homogeneous with re-
gard to age, parity, previous IGR history, clinical
history, food and toxic habits, and gestational age
on admission and at the time of delivery.
— Group A. Treatment groups: made up of 44
patients
— Group B. Control group: made up of 54 pa-
tients.
The size difference between groups was due to an
error while transcribing the randomized lists, so
that five patients which should have been assigned
to the treatment group, became part of the control
group. Since the error was random itself, the pa-
tients were not excluded from the study.
At the time the diagnostic suspicion was raised,
the patients were admitted into our Center's High
Risk Unit. Complete hematological, coagulation,
biochemical and hormone level tests were per-
formed on all patients. The biochemicaly results
were normal, and a slight iron differency anemia
was detected in a third of them. This was corrected
with the appropiate medication. Serum tests to
detect rubella, toxoplasmosis, cytomegalovirus
and lysteriosis were done in order to discard any
possible infectious etiology. The results were neg-
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ative in all cases. Likewise, amniocentesis was per-
formed to evaluate fetal maturity by the Clements
test and by orange cell determination as a gesta-
tional age marker. The results of these tests will
be published elsewhere.
Maternal well-being studies included: determina-
tion of maternal constants, uterine activity, fetal
movements and fetal heart rate, every 12 hours;
uterine height, abdominal perimeter and body
weight, every 24 hours; non-stress tests (NST)
every 48 hours; and weekly sonographic controls
along with blood and biochemical tests.
The patients from Group A remained in hospital
until the end of pregnancy with a mean stay of
15 + 5 days; they received Beta-mimetic treatment
with ritodrine at a dose of 10 mg/8 hours, P. O.
(table I). Furthermore, they were prescribed ab-
solute rest in bed, high caloric, high protein and
high carbohydrate diet with an average caloric
intake of 60 Kcal/Kg body weight per day, along
with vitamin and mineral (Ca, Fe, Folic acid,
vitamin Bi2) suplements.
The patients from the Control Group were dis-
charged following an average stay of 7 ± 3 days.
They were prescribed home rest, high caloric diet
and measurement of fetal movements twice daily.
The patient was hospitalized if the number of
movements was less than five in one hour. This
group was not treated with ritodrine. They under-
went weekly outpatient visits, where blood and
biochemied tests were done. NST, and vital signs






































Fetal weight assessment and classification in the
Fetal Growth Retardation Group was decided in
relation to gestational age and according to our
Center's weight curve [1].
We defined acute fetal distress as the presence of
a fetal pH value lower than 7.25 in the absence of
maternal acidosis. At delivery we considered path-
ological any pH values under 7.20 when obtained
from the umbilical artery.
The statistical analysis was done using the Ordered
Chi square test with YATES' correction when nec-











FHR: fetal heart rate. UA: uterine activity. UH: uterine
height. AC: abdominal circunference
Figure 1. Prevalence of IUGR in treatment group versus
control group.
3 Results
The prevalence of low birth weight infants for
their gestational age was 47.73% (21 cases) in the
treatment group and 40.74% (22 cases) in the
control group (figure 1). The difference is not
significant. Mean weights were similar in both
groups: 2.903 ± 407 gm. in group A, and 2.886
± 410 gm. in group B. The mean weight of IGR
infants was 2.565 ±217 gm. in the treatment
group and 2.504 + 253 in the control group. The
weight of normal newborns was 3.213 ± 323 gm.
in the first group, and 3.063 + 263 gm. in the
second one (table II).
Of the deliveries 40.9% of labors in the treatment
group were induced. Half were induced for fetal
causes (cardiotocographic alterations following
either NST or stress test, meconium in the am-
niotic fluid or lack of sonographic growth). The
J. Perinat. Med. 16 (1988)
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control group showed similar findings. There were
35.18% induced labors, and of these, 47.35% were
due to fetal indications (table III).
Of the cases in the treatment group 18.18% were
delivered by cesarean section, of which 62.5%
were due to fetal distress. The control group
showed similar figures: 16.66% cesarean sections
with 77.7% of them due to fetal distress.
We observed an incidence of 20.45% of acute fetal
distress in the study group against 12.96% in the




































































• p = NS + (%)
J. Perinat. Med. 16 (1988)
The group under study demonstrated rate of
6.82% pathological pH values in the umbilical
artery, while the rate of abnormal values in the
control group was 18.52%. In both groups, the
greatest percentage of acidotic pH values was
found in the IGR cases. Considering these data
more closely we observed that IGR cases receiving
b-mimetic treatment showed a rate of 9.09%,
while the incidence of low pH values was 31.48%
in the control group. In spite of the values, the
difference is not statistically significant (table IV).
Perinatal mortality was 0% in the treatment group
and 37% in the control group, the latter is due to
two deaths: 1 antepartum death due to an umbil-
ical cord knot and 1 postpartum death due to
sepsis. These deaths may not be attributed to fetal
growth retardation, poor management of fetal sta-
tus or lack of administration of vasodilator drugs.
4 Discussion
A prolonged hospital stay has been considered a
potentially positive factor in the treatment of IGR
since this permits closer observation of the mother
and fetus. On one hand, the hospitalized patient
eats more once better diet than would be expected
at home, and likewise, the frequency of surveil-
lance of fetal well-being is increased (FHR/12
hours, NST/48 hours, etc.), thus reducing the time
between them.
In our series we did not find any differences in the
weight of newborns or in the perinatal outcome
results between hospitalized patients and those
who remained at home with self-evaluation of fetal
movements following a reactive non stress test.
The antepartum fetal death due to a knot in the
umbilical cord may not be atributed to a reduced
frequency of NST performed since this is an acute
obstetric accident which may coexist with a reac-
tive pattern only a few hours earlier. In a review
of 19 series published in the literature [6] on the
incidence of false reactive NSTs (a false reactive
NST means that fetal death took place within 7
days of obtaining a positive result), we found 62
fetal deaths from a total of 14976 (incidence of
false reactives 0.41%). The cause of death was
specifically mentioned in 26 fetal deaths, 11 of
which (42%) were associated with umbilical cord
problems.
With regard to B-mimetic drug therapy, their hy-
pothetical beneficial effect on fetal growth may be
deduced from their effects at different levels: In
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the first place, it induces an increase in plasma
blood sugar in the maternal curculation [3, 12],
and an increase in the heart volume per minute,
leading to an increase in uterine blood flow [10].
Thus, an increased blood flow is available to the
intervillious space, with a consequent increase in
O2 and other elements, especially glucose, which
was previously increased [5].
At the level of the placenta, a vasodilatation of
villious capillaries was seen [11], with an improved
fetal blood transport capacity, suggesting an im-
proved exchange and greater supply of energetic
substances. Finally, an increase in circulating glu-
cose was seen at the fetal level [3], possibly due to
different mechanisms. On the one hand, diffusion
of a greater amount of glucose from the mother
to the fetus, a finding we mentioned already, and
on the other hand, the direct effect of B-niimetic
drugs on the fetus.
These hypothetical beneficial effects of Beta-ago-
nists, do not seem to have a clear clinical expres-
sion unless they are administered orally in low
doses. In a multicenter study carried out in 1972
by THIERY et al. [13], which assessed the effects
that B-mimetic drugs had on premature labor, it
was observed that newborns of mothers treated
with these agents weighted more than newborns
of mothers receiving a placebo.
The observations carried out by MERKATZ et al.
[9] and FALK LARSON et al. [7] disagree with them.
The latter authors, in a study similar to THIERY'S,
noticed that although the weight of newborns of
treated mothers was somewhat higher (97 gm.)
than those of non-treated mothers, the difference
between groups was not statistically significant.
Likewise, in our series, newborns of mothers re-
ceiving treatment weighed 17 gm. more than new-
borns from mothers in the control group, and this
finding lacks statistical significance.
In summary, we do not feel that prolonged hos-
pital stay with oral ritodrine administration has
demonstrated any utility in the treatment of IGR
of unknown etiology — not even as symptomatic
measures.
Research in this field most likely will concentrate
on establishing the etiopathogenity of IGR. Only
a deep knowledge of the factors which cause an
interruption or retardation of the intrauterine fetal
growth process may bring about an efficient treat-
ment.
Summary
A group of 98 third trimester pregnant women whose
ultrasonographic studies raised the suspicion of intra-
uterine fetal growth retardation was studied. The pa-
tients were randomly assigned to two groups: Group A
(Treatment group: 44 patients) and Group B (Control
group: 54 patients).
All patients were admitted to the hospital upon diagnosis
for baseline evaluation. Those in Group A remained in
the hospital until delivery (mean stay 15 + 5 days) and
received treatment with 10 mg/t. i. d. of p. o. ritodrine.
Group B patients were discharged after an average stay
of 7 ± 3 days. This group was not treated with ritodrine,
and they were seen weekly in an outpatient setting.
The prevalence of low-birth-weight infants for their ges-
tational age was 47.73% in the treatment group and
40.74% in the control group. Of the deliveries in the
treatment group, 40.9% were induced (half for fetal
indications). In the control group 35.18% of the induced
labors was (47.35% for fetal indications). Of the cases
in the treatment group 18.18% were delivered by cesar-
ean section, of which 62.5% were performed for fetal
distress. The control group showed similar figures:
16.66% cesarean sections with 77.7% of them done for
fetal distress. We observed an incidence of 20.45% of
acute fetal distress in the study group against 12.96% in
the control group. Such a difference is not statistically
significant. The group under study demonstrated a rate
of 6.82% pathological pH value in the umbilical artery,
while the rate of abnormal values in the control group
was 18.52%. In both groups, the greatest percentage of
acidotic pH was observed in patients with IGR.
From these results we cannot infere any advantage of
prolonged hospital stay with oral ritodrine administra-
tion in the treatment of intrauterine fetal growth retar-
dation of unknown etiology.
Keywords: Intrauterine growth retardation, long term hospital stay, ritodrine.
Zusammenfassung
Langzeithospitalisierung und Betamimetika bei der Be-
handlung der intrauterinen Wachstumsretardierung unbe-
kannter Ätiologie
Wir untersuchten 98 Frauen im letzten Schwanger-
schaftstrimester, bei denen ultrasonographisch der Ver-
dacht auf eine intrauterine Wachstumsretardierung
J. Perinat. Med. 16 (1988)
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(IUGR) erhoben wurde. Nach Randomisierung wurden
zwei Gruppen gebildet: Gruppe A stellte mit 44 Patienten
die therapierte Gruppe dar, in der Kontrollgruppe B
befanden sich 54 Patienten.
Alle Patientinnen wurden nach der Verdachtsdiagnose
einer Basisuntersuchung unterzogen. Die Frauen der
Gruppe A blieben bis zur Entbidnung im Krankenhaus
(mittlerer Aufenthalt 15 ± 5 Tage) und erhielten 3 10
mg Ritodrin/d. Patientinnen der Gruppe B wurden nach
durchschnittlich 7 + 3 Tagen entlassen und nicht mit
Ritodrin behandelt. Es erfolgten wöchentlich ambulante
Kontrollen.
Small-for-date-Kinder traten mit einer Prävalenz von
47,73% in Gruppe A bzw. von 40,74% in Gruppe B auf.
In Gruppe A wurden 40,9% der Geburten eingeleitet
(davon 50% aus fetaler Indikation), in Gruppe B 35,18%
(zu 47,35% aus fetaler Indikation). In Gruppe A betrug
die Sektiorate 18,18%, davon gingen 62,5% auf ein
fetales Distress zurück. Die Kontrollgruppe liefert ähn-
liche Zahlen: 16,66% Sektiorate, davon 77,7% wegen
fetalem Distress. Ein akuter fetaler Distress wurde in
Gruppe A in 20,45% der Fälle beobachtet, während es
in der Kontrollgruppe bei 12,96% auftrat. Dieser Un-
terschied ist statistisch nicht signifikant. In der Gruppe
A traten pathologische pH-Werte in der Umbilikalarterie
in 6,82% der Fälle auf, während in der Kontrollgruppe
bei 18,52% abnorme pH-Werte gemessen wurden. In
beiden Gruppen waren azidotische Werte gehäuft, wenn
tatsächlich eine IUGR vorlag.
Unsere Ergebnisse zeigen, daß die Langzeithospitalisie-
rung und orale Ritodringabe bei der Behandlung der
IUGR unbekannter Ätiologie keine Vorteile bzw. Ver-
besserungen liefern.
Schlüsselwörter: Intrauterine Wachstsumsretardierung, Langzeithospitalisierung, Ritodrin.
Resume
Hospitalisation prolongee et betaminetiques dans le trai-
tement des retards de la croissance intra-uterins d'etiologie
inconnue
On a etudie un groupe de 98 femmes enceintes au cours
du troisieme trimestre de leur grossesse, chez lesquelles
les echographies avaient fait suspecter un retard de crois-
sance intra-uterin. Les patientes ont ete reparties en deux
groupes differents par randonisation:
— groupe A: groupe traite = 44 patientes
— groupe B: groupe controle = 54 patientes
Toutes les patientes ont ete hospitalisees des le diagnostic
pour une evaluation de base. Gelles du groupe A sont
restees hospitalisees jusqu'ä Faccouchement (duree
moyenne du sejour 15 + 5 jours) et ont regu un traite-
ment de 10 mg/t. i. d. de ritodrine per 05. Les patientes
du groupe B sont sorties apres un sejour moyen de 7 + 3
jours, ce groupe n'avait pas de ritodrine et etait controle
hebdommadairement en ambulatoire.
La prevalence des enfants de faible poids de naissance
pour Tage gestationnel a ete de 47,73% dans le groupe
traite et de 40,74% dans le groupe controle.
Dans le groupe traite 40,9% des accouchements ont ete
declenches (50% pour causes foetales), alors que dans le
groupe B ily a eu 35,18% de declenches (47,35% pour
indication foetale).
18,18% des patientes du groupe traite ont eu une cesa-
rienne, parmi lesquels 62,5% pour souffrance foetale. Le
groupe controle est similaire: 16,66% de cesariennes avec
77,7% secondaires ä une souffrance foetale.
Nous avons observe une incidence de 20,45% de souf-
france foetale a'igue dansle groupe traite contre 12,95
dans le groupe controle. Cette difference n'est pas sta-
tistiquement significative. Le groupe traite a presente un
taux de 6,82% de pH dans Fartere ombilicale patholo-
giques, alors que le taux de valeurs anormales dans le
groupe controle etait de 18,52%.
Dans les deux groupes le pourcentage le plus eleve de
pH acidotique a ete observe dans les RCIU.
A partir de ces resultats, nous ne pouvons tirer d'avan-
tages a l'hospitalisation prolongee et ä la prise de rito-
drine pour le traitement du retard de croissance intra-
uterin sans cause connuc.
Mots-cles: Hospitalisation de longue duree, retard de croissance intra-uterin. ritodrine.
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